Simvastatin reduces forearm vascular responsiveness to norepinephrine [1]

Atherosclerosis

Volumn 131, Issue 2, 1997, Pages 263-264

  Abbott, D ^a   Daher, A ^a   Manwaring, P ^a   Howes, L G ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; N(G) NITROARGININE METHYL ESTER; NORADRENALIN; SIMVASTATIN;

ATHEROGENESIS; ATHEROSCLEROSIS; FOREARM BLOOD FLOW; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LETTER; PRIORITY JOURNAL; VASODILATATION;

EID: 0030919082     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)06107-8     Document Type: Article

References (4)

1. Stroes E, Koomans H, de Buin T, Rabelink T. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995;346:467–471.
2. Galle J, Bassenge E, Busse R. Oxidized low density lipoproteins potentiate vasoconstrictions to various contractile agonists by direct interaction with vascular smooth muscle. Circ Res 1990;66:1287–1293.
3. Straznicky N, Howes LG, Lam W, Louis WJ. Pravastatin reduces cardiovascular reactivity to noradrenaline and angiotensin II in hypercholesterolmic hypertensives. Am J Cardiol 1995;75:582–586.
4. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994;94:2511–2515.